Advanced Micro Devices, Inc. vs Bristol-Myers Squibb Company: Strategic Comparison

This in-depth comparison examines Advanced Micro Devices, Inc. and Bristol-Myers Squibb Company across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Advanced Micro Devices, Inc. on its own, evaluating Bristol-Myers Squibb Company, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Advanced Micro Devices, Inc. and Bristol-Myers Squibb Company is widest.

On the headline numbers, Advanced Micro Devices, Inc. reports annual revenue of $34.6B against $48.2B for Bristol-Myers Squibb Company, while their respective market capitalizations stand at $999.5B and $127.5B. Both Advanced Micro Devices, Inc. and Bristol-Myers Squibb Company are headquartered in United States, so they compete in a shared home market and regulatory environment.

Advanced Micro Devices, Inc.: Advanced Micro Devices spent most of its first four decades as Intel's smaller x86 rival, competitive in some generations and close to failure in others. It moved its fabs into GlobalFoundries in 2009, and after Lisa Su became CEO in October 2014 it concentrated its engineering budget on one clean-sheet CPU core, Zen. Ryzen and EPYC arrived in 2017, and the Xilinx and Pensando deals in 2022 widened the portfolio past CPUs and graphics. AMD now designs server and desktop processors, Radeon graphics, Instinct AI accelerators, and adaptive SoCs, and supplies the semi-custom chips inside the PlayStation 5 and Xbox Series consoles.

Bristol-Myers Squibb Company: Bristol Myers Squibb (BMS) is a U.S. biopharmaceutical company headquartered in Princeton, New Jersey, and listed on the New York Stock Exchange as BMY. It develops and sells prescription medicines for cancer, blood disorders, immune diseases, heart disease and schizophrenia. Its best-known products are Eliquis, the anticoagulant it sells with Pfizer, and Opdivo, a PD-1 checkpoint inhibitor. With $48.2 billion of 2025 revenue and a market value of about $127 billion at the end of September 2026, it is one of the largest U.S. drugmakers by sales.

Advanced Micro Devices, Inc. and Bristol-Myers Squibb Company pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Advanced Micro Devices, Inc. and Bristol-Myers Squibb Company.

Advanced Micro Devices, Inc. business model: Advanced Micro Devices runs a fabless semiconductor model. It designs CPUs, GPUs, AI accelerators, FPGAs, and adaptive SoCs, and contracts the wafer manufacturing to outside foundries, primarily TSMC. That structure keeps leading-edge fabrication off AMD's balance sheet and makes engineering its largest investment: research and development cost $8.1B in FY2025, about 23% of revenue. Revenue comes from three reportable segments. Data Center, $16.6B in FY2025, covers EPYC server CPUs, Instinct AI accelerators, Pensando DPUs, AI network interface cards, and adaptive SoCs sold to cloud providers, enterprises, and HPC customers. Client and Gaming, $14.6B, covers Ryzen desktop and notebook processors, chipsets, Radeon discrete graphics, and the semi-custom SoCs inside PlayStation and Xbox consoles; within it Client was $10.6B and Gaming $3.9B. Embedded, $3.5B, covers the Xilinx-derived FPGA, system-on-module, and adaptive SoC lines sold into telecom, aerospace, defense, automotive, and industrial equipment. The design lever is chiplets: AMD splits a processor into several smaller dies joined by Infinity Fabric, which raises usable yield and lets it mix process nodes inside one package.

Bristol-Myers Squibb Company business model: BMS discovers, licenses or buys drug candidates, takes them through clinical trials, and sells approved medicines under patent protection to wholesalers, specialty pharmacies and hospitals. Net product sales were $46.8 billion of the $48.2 billion total in 2025; alliance, royalty and other revenues made up the remaining $1.4 billion, including royalties from Merck on Winrevair. Eliquis is developed and sold with Pfizer, which shares its costs and profits. About 69 percent of 2025 revenue came from the United States, so U.S. pricing policy matters more to BMS than to most European rivals. Because every patent runs out, the model depends on replacing revenue: BMS paid $74 billion for Celgene in 2019, $13.1 billion for MyoKardia in 2020 and about $23 billion for Karuna, Mirati and RayzeBio in early 2024.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Advanced Micro Devices, Inc. stack up against those of Bristol-Myers Squibb Company.

Advanced Micro Devices, Inc. competitive advantage: AMD's advantage is design and packaging execution without fab ownership. Because it buys capacity from TSMC instead of running leading-edge fabs, it can move to a newer process node as soon as the foundry has one in volume. Its chiplet approach assembles a processor from smaller dies linked by Infinity Fabric, which improves usable yield and makes high core-count parts cheaper to build than a single large die. Zen-based EPYC and Ryzen processors converted that into server and client share gains against Intel, and 3D V-Cache gives the Ryzen X3D desktop parts a cache advantage in games.

Bristol-Myers Squibb Company competitive advantage: BMS's advantage is its expertise in oncology and its large commercial and regulatory organization. Developing a cancer immunotherapy is complex, and winning approval from regulators and getting doctors to prescribe it requires an established global sales and regulatory team. Smaller biotech companies often lack that infrastructure, so they partner with or sell to a company like BMS to bring their discoveries to market.

Future prospects matter as much as current results. The growth strategies below explain how Advanced Micro Devices, Inc. and Bristol-Myers Squibb Company each plan to expand from here.

Advanced Micro Devices, Inc. growth strategy: AMD's growth plan centers on data center AI, funded by $8.1B of research and development in FY2025. It has bought capability rather than waiting to build it: Xilinx in February 2022 for FPGAs and adaptive computing, a deal announced in October 2020 at about $35B in stock and worth roughly $49B at close; Pensando in May 2022 for DPUs at about $1.9B; Silo AI in August 2024 for AI software engineering at about $665M; and ZT Systems in March 2025 for rack-scale systems design. The aim is to sell complete AI racks that combine EPYC CPUs, Instinct accelerators, AI networking, and ROCm software instead of individual chips, while Ryzen and Radeon keep funding the effort.

Bristol-Myers Squibb Company growth strategy: BMS is pursuing growth on three fronts. First, scaling the Growth Portfolio (Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi, Opdualag, Cobenfy and others), which rose 17 percent to $26.4 billion in 2025 and 15 percent to $7.56 billion in the second quarter of 2026. Second, buying and licensing late-stage science: Mirati ($4.8 billion plus a contingent value right of up to $1 billion), RayzeBio ($4.1 billion) and Karuna ($14 billion) closed in early 2024; a June 2025 deal with BioNTech for the bispecific BNT327 carried $1.5 billion upfront and up to $11.1 billion in total; and Orbital Therapeutics was bought for $1.5 billion in October 2025 for in vivo CAR-T in autoimmune disease. Third, cost cuts: a $1.5 billion savings program announced in 2024 was extended in 2025 with a further $2 billion targeted by the end of 2027.

A closer look at the financial trajectory of Advanced Micro Devices, Inc. and Bristol-Myers Squibb Company rounds out the comparison.

Advanced Micro Devices, Inc.: AMD's decade is a turnaround with a paper trail. Revenue fell to $4.0B in 2015 and the company lost $660M; its market value ended that year near $2.3B. Zen-based Ryzen and EPYC parts, and Intel's process delays, shifted the mix toward servers and then AI accelerators. FY2025 revenue was $34.6B, up 34% from $25.8B, with net income of $4.3B, a 50% gross margin, $8.1B of research and development spending, and $4.1B of marketing, general and administrative expense. Cash, cash equivalents, and short-term investments rose to $10.6B from $5.1B a year earlier, against $3.3B of total debt principal. The result also absorbed about $440M of net inventory and related charges tied to US export controls on Instinct MI308 products.

Bristol-Myers Squibb Company: Revenue grew from $19.4 billion in 2016 to $42.5 billion in 2020 as Celgene's sales were added, and has stayed between $45.0 billion and $48.3 billion since 2021. Net earnings are far less stable because BMS expenses acquired in-process R&D: the $11.4 billion MyoKardia charge produced a $9.0 billion net loss in 2020, and the Karuna charge produced an $8.9 billion loss in 2024. Cash generation is steadier, with free cash flow of about $12.8 billion in 2025. That cash funds a dividend raised for a 17th straight year in February 2026, to $0.63 a quarter, and debt reduction, from $51.2 billion at the end of 2024 to $47.2 billion a year later. On July 30, 2026 BMS raised its 2026 revenue guidance to $49.0 to $50.0 billion, from $46.0 to $47.5 billion, after second-quarter revenue rose 6 percent to $12.97 billion.